Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pd-1 Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07110103
What this trial is testing

Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC

Who this might be right for
SCLCSCLC, Extensive Stage
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 20
Testing effectiveness (Phase 2)UnknownNCT06396637
What this trial is testing

PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC

Who this might be right for
Pancreatic Adenocarcinoma Metastatic
Sun Yat-sen University 20
Not applicableLooking for participantsNCT06550921
What this trial is testing

Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

Who this might be right for
Advanced Hepatocellular CarcinomaOligometastasisAblation+2 more
Sun Yat-sen University 60
Not applicableLooking for participantsNCT03888950
What this trial is testing

Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy

Who this might be right for
Metastatic Melanoma
Centre Hospitalier Universitaire de Nice 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06547476
What this trial is testing

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Who this might be right for
Breast Cancer
Guangdong Provincial People's Hospital 40
Testing effectiveness (Phase 2)UnknownNCT03793725
What this trial is testing

A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC

Who this might be right for
Hepatocellular Carcinoma
Yanqiao Zhang 30
Early research (Phase 1)Study completedNCT02179918
What this trial is testing

4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)

Who this might be right for
Advanced Solid Tumors
Pfizer 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT06773910
What this trial is testing

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Who this might be right for
Limited Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC 250
Testing effectiveness (Phase 2)WithdrawnNCT03169738
What this trial is testing

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Who this might be right for
Non-small Cell Lung Cancer
ImmunityBio, Inc.
Not applicableLooking for participantsNCT06549855
What this trial is testing

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Who this might be right for
Endometrial CancerEndometrioid CarcinomaMismatch Repair Deficiency
Peking University People's Hospital 10
Testing effectiveness (Phase 2)UnknownNCT04371796
What this trial is testing

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Who this might be right for
Lung DiseasesNeoplasmsRespiratory Tract Diseases+2 more
Sichuan Cancer Hospital and Research Institute 20
Early research (Phase 1)Active Not RecruitingNCT03362060
What this trial is testing

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerMetastatic Breast Cancer
Massachusetts General Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT03606174
What this trial is testing

Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma Ureter+2 more
Mirati Therapeutics Inc. 260
Testing effectiveness (Phase 2)Study completedNCT02834052
What this trial is testing

Pembrolizumab + Poly-ICLC in MRP Colon Cancer

Who this might be right for
Metastatic Colon CancerSolid Tumor
Asha Nayak 42
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05970627
What this trial is testing

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Who this might be right for
Adenocarcinoma of the StomachAdenocarcinoma of Esophagogastric JunctionEpstein-Barr Virus-Associated Gastric Carcinoma
Yu jiren 30
Not applicableLooking for participantsNCT04294771
What this trial is testing

JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors

Who this might be right for
MyocarditisCardiomyopathiesHeart Diseases+3 more
Groupe Hospitalier Pitie-Salpetriere 500,000
Not applicableStudy completedNCT03964298
What this trial is testing

Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma

Who this might be right for
Uveal Melanoma
Institut Curie 100
Testing effectiveness (Phase 2)Looking for participantsNCT07227636
What this trial is testing

Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

Who this might be right for
Colorectal CancerRectal Cancer
Memorial Sloan Kettering Cancer Center 284
Early research (Phase 1)UnknownNCT03971214
What this trial is testing

PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer

Who this might be right for
Extensive-stage Small Cell Lung CancerRadiotherapyImmunotherapy
Chinese Academy of Medical Sciences 6
Testing effectiveness (Phase 2)Study completedNCT04704154
What this trial is testing

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Who this might be right for
Solid Tumors
Bayer 175
Next Page